You are absolutely and completely correct. LDN for Crohn's Disease appears to be efficacious-and is more significant in that it is a very tolerable medication. There is much to be considered here IMO, including the relationship that was established between Cytocom and IMUN and what was accomplished by the funding into Cytocom for which shares were given, therefore significantly diluting IMUN's ownership.
News 
Market Data 
Discover 
